Brought to you by 
Tasly pays up to $65mm for Chinese rights to Mesoblast's MPC150IM and MPC25IC cardio candidates
19 Jul 2018
Executive Summary
Tasly Pharmaceutical Co. Ltd. licensed exclusive rights in China to develop, manufacture, and commercialize Mesoblast Ltd.'s allogeneic mesenchymal precursor cell (MPC) cardiovascular disease candidates MPC150IM and MPC25IC.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tasly pays up to $65mm for Chinese rights to Mesoblast's MPC150IM and MPC25IC cardio candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice